The purpose of this study is to investigate advanced solid tumors with KRAS p.G12C mutation. This study involves two phases: a dose escalation phase and a dose expansion phase.
This study evaluates the safety and tolerability of the investigational medication in combination with another treatment. It also looks at how the body processes the medication and checks the preliminary effectiveness and safety of the treatment.
- Who can participate: Adults with advanced solid tumors with KRAS p.G12C mutation, who have no other treatment options or cannot tolerate standard treatments, may participate. Participants must have a life expectancy of at least 3 months and be able to swallow oral medications.
- Study details: Participants will take an investigational medication in combination with another treatment. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand